| Code | CSB-RA723415MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to dresbuxelimab, targeting NT5E (ecto-5'-nucleotidase), also known as CD73. NT5E is a cell surface enzyme that catalyzes the conversion of extracellular adenosine monophosphate to adenosine, playing a critical role in purinergic signaling and immune regulation. By generating adenosine in the tumor microenvironment, NT5E promotes immunosuppression through adenosine receptor activation on immune cells, thereby inhibiting anti-tumor T cell responses and natural killer cell function. Elevated NT5E expression has been associated with various malignancies, including triple-negative breast cancer, ovarian cancer, and melanoma, where it contributes to immune evasion and poor prognosis.
Dresbuxelimab is a therapeutic antibody developed to block NT5E enzymatic activity, aiming to restore anti-tumor immunity and enhance the efficacy of cancer immunotherapies. This biosimilar antibody serves as a valuable research tool for investigating NT5E-mediated immunosuppression, studying adenosine pathway mechanisms in cancer biology, and exploring combination strategies with immune checkpoint inhibitors in preclinical models.
There are currently no reviews for this product.